Skip to main content
. 2022 Dec 12;12:1042525. doi: 10.3389/fonc.2022.1042525

Figure 3.

Figure 3

CT-scan performed in March 2021, after four months of Lenvatinib, showing a dimensional reduction of latero-cervical lymphadenopathies (maximum diameter of 2 cm) (A), and of left thyroid lobe (3x4,7 cm) (B), and a mild increase of the hepatic lesion (17 mm vs 12 mm) (C).